- The Pfizer COVID-19 vaccine has proven 94 percent effective in a study involving 1.2 million people in Israel, the first peer-reviewed real world research confirming the power of mass immunization campaigns to bring the pandemic to a close. https://www.nejm.org/doi/10.1056/nejmoa2101765 525 comments science
- Effectiveness of the BNT162b2 mRNA Vaccine in Israel https://www.nejm.org/doi/pdf/10.1056/nejmoa2101765?articletools=true 3 comments science
Linking pages
- mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants | Scientific Reports https://www.nature.com/articles/s41598-022-06629-2 1849 comments
- Delta Variant: Everything You Need to Know - by Tomas Pueyo https://unchartedterritories.tomaspueyo.com/p/delta-variant-everything-you-need 404 comments
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2119451 237 comments
- Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2115463 145 comments
- CIMB | Free Full-Text | Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line | HTML https://www.mdpi.com/1467-3045/44/3/73/htm 99 comments
- BNT162b2 Vaccine Booster and Mortality Due to Covid-19 | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2115624 69 comments
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months | NEJM https://www.nejm.org/doi/10.1056/nejmoa2114583 58 comments
- Covid-19 Breakthrough Infections in Vaccinated Health Care Workers | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2109072 56 comments
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2108891 50 comments
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant | NEJM https://www.nejm.org/doi/full/10.1056/nejmoa2108891?query=featured_coronavirus 50 comments
- Pfizer Covid vaccine 94% effective in peer-reviewed, real-world mass study | Coronavirus | The Guardian https://www.theguardian.com/world/2021/feb/25/pfizer-covid-vaccine-94-effective-study-of-12m-people-finds 40 comments
- Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2110475?query=featured_home 35 comments
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase | NEJM http://dx.doi.org/10.1056/nejmoa2113017 24 comments
- COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room - The Lancet Microbe https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00069-0/fulltext 24 comments
- Myocarditis after Covid-19 Vaccination in a Large Health Care Organization | NEJM https://www.nejm.org/doi/full/10.1056/nejmoa2110737 18 comments
- CIMB | Free Full-Text | Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line https://www.mdpi.com/1467-3045/44/3/73/htm?s=09 16 comments
- Coronavirus: Will Spain be able to vaccinate 70% of the adult population by the end of summer? | Society | EL PAÍS English Edition https://english.elpais.com/society/2021-03-02/will-spain-be-able-to-vaccinate-70-of-the-adult-population-by-the-end-of-summer.html 13 comments
- COVID is surging in the world's most vaccinated country. Why? https://theconversation.com/covid-is-surging-in-the-worlds-most-vaccinated-country-why-160869 10 comments
- SARS-CoV-2 Infection after Vaccination in Health Care Workers in California | NEJM https://www.nejm.org/doi/full/10.1056/nejmc2101927 10 comments
- Vaccines | Free Full-Text | The Safety of COVID-19 Vaccinations—We Should Rethink the Policy | HTML https://www.mdpi.com/2076-393X/9/7/693/htm 9 comments
Linked pages
- Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use | Johnson & Johnson https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial 23 comments
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine | NEJM https://www.nejm.org/doi/full/10.1056/nejmoa2035389 18 comments
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2034577 1 comment
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04368728 0 comments
- COVID-19 Treatment Guidelines https://covid19treatmentguidelines.nih.gov/ 0 comments
- VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2208822 0 comments
Related searches:
Search whole site: site:www.nejm.org
Search title: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting | NEJM
See how to search.